Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men
This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.
The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.
LambdaGuide measurements will not be used to guide or modify clinical care.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Descrizione dettagliata
This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.
The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.
Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.
During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.
For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.
Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.
Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.
The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Sarah Lapp
- Numero di telefono: 678-231-0685
- Email: sarah@lambdasurgical.com
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Reclutamento
- PINE (Prostate Institution of New England)
-
Contatto:
- Alethia Chan
- Numero di telefono: 857-800-2305
- Email: chanalethia@gmail.com
-
Investigatore principale:
- Louis Liou, MD, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.
Descrizione
Inclusion Criteria:
- Adult male subject (22 years of age or older).
- Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
- Able and willing to provide informed consent before study participation.
- Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
- Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
- Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.
Exclusion Criteria:
- Participation is expected to interfere with or materially delay standard clinical care.
- Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
- Inability to provide informed consent.
- Inability to use the required compatible cystoscope or approved study configuration.
- Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: CASE_ONLY
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Clinical measurement feasibility
Lasso di tempo: Procedure duration
|
Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained. |
Procedure duration
|
|
Primary safety endpoint
Lasso di tempo: From procedure date to 30 days after (+/-5 days)
|
Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events. |
From procedure date to 30 days after (+/-5 days)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Calibration success
Lasso di tempo: During Procedure
|
Calibration success |
During Procedure
|
|
Camera deployment and expected image display
Lasso di tempo: During Procedure
|
Camera deployment and expected image display |
During Procedure
|
|
Spatial capture success
Lasso di tempo: During Procedure
|
Spatial capture success |
During Procedure
|
|
Valid point-selection success
Lasso di tempo: During Procedure
|
Valid point-selection success |
During Procedure
|
|
Successful measurement completion
Lasso di tempo: During Procedure
|
Successful measurement completion |
During Procedure
|
|
Calibration and measurement time
Lasso di tempo: During Procedure
|
Calibration and measurement time (descriptive only) |
During Procedure
|
|
Procedure interference
Lasso di tempo: During Procedure
|
Procedure interference |
During Procedure
|
|
User acceptance
Lasso di tempo: During Procedure
|
User acceptance - based on Investigator Questionnaire |
During Procedure
|
|
Observational comparative measurements (
Lasso di tempo: During Procedure
|
Observational comparative measurements (descriptive only) |
During Procedure
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Louis Liou, MD, PhD, PINE - Prostate Institution of New England
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- LG-GU-001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .